Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Biochemical markers of bone turnover in hemodialysis patients treated with paricalcitol (CROSBI ID 535492)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Pavlović, Draško ; Vrkić, Nada ; Tešija Kuna, Andrea ; Pavlović, Nikola ; Mirošević, Gorana Biochemical markers of bone turnover in hemodialysis patients treated with paricalcitol // Hemodialysis international / Nissenson, Allen R. (ur.). 2008. str. 143-144

Podaci o odgovornosti

Pavlović, Draško ; Vrkić, Nada ; Tešija Kuna, Andrea ; Pavlović, Nikola ; Mirošević, Gorana

engleski

Biochemical markers of bone turnover in hemodialysis patients treated with paricalcitol

Vitamin D therapy is important in the management of secondary hyperparathyroidism (SHPT). The effects of calcitriol and its an-alogs on PTH secretion and parathyroid gland hyperplasia have been well established. Several studies have also demonstrated the effect on bone metabolism. Besides its selective effect on vitamin D receptor, it seems that paricalcitol has a different effect on bone cells The aim of the study was to assess the short-term effect of paricalcitol on bone metabolism in hemodialysis patients with secondary hyperparathyroidism by using biochemical markers of bone formation and resorption. Seven hemodialysis patients (PTH > 300 pg/ml) were treated with paricalcitol. The dose of par-icalcitol was 5 meg 3 times per week. At the start of therapy and 3 months later serum total procollagen 1 N-propeptide (P1NP) and osteocalcin (OC) as bone formation markers, and beta-cross laps (Beta-CTX) as a bone resorption marker, were determined by the electrochemoluminescence immunoassay. PTH was deter-mined by radioimmunometric assay. All patients underwent hemodialysis treatment for 4 hours 3 times per week. Dialysate calcium concentration was 1.5mmol/L ; sevelamer hydrochloride was used as a phosphate binder. After 3 months of treatment, a significant reduction, of PTH (average 68%) was observed. At the same time, the average reduction of OC was 26%, P1NP 41%, and Beta-CTX 51%. The results indicate the reduction of bone turn-over, i.e. bone formation, and a bit more bone resorption. The reduction of Beta-CTX was the closest to the reduction of PTH. We need to confirm these results on larger group of patients and for a longer follow up period.

paracalcitol; hemidialysis; bone markers

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

143-144.

2008.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Hemodialysis international

Nissenson, Allen R.

Columbia (MO): Wiley-Blackwell

1492-7535

Podaci o skupu

Annual Conference on Peritoneal Dialysis (28 ; 2008) ; International Symposium on Hemodialysis (14 ; 2008) ; Annual Symposium on Pediatric Dialysis (19 ; 2008)

poster

02.03.2008-04.03.2008

Orlando (FL), Sjedinjene Američke Države

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija

Indeksiranost